Amgen announced multiple Europe-focused oncology deals that together could be worth roughly $1.46 billion, including the acquisition of Dark Blue Therapeutics and a license pact with Disco Pharmaceuticals. The transactions add a degrader-like program targeting AML and a novel cancer cell-surface target to Amgen’s pipeline, diversifying its discovery engines and bolstering near-term oncology assets. Amgen is paying up to $840 million for Dark Blue to secure a protein-degradation approach active in acute myeloid leukemia and signed a separate $618 million licensing deal with Disco for rights to a distinct cell-surface oncology target. The moves reflect Big Pharma’s preference for targeted buys and partnerships to accelerate oncology portfolios while accessing European science.